PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Linda R. Duska, MD, MPH - Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies
Go online to PeerView.com/BTK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of gynecologic oncology experts reviews the clinical evidence supporting the use of novel targeted, immunotherapeutic, and antibody-based strategies in gynecologic cancers. Learn the practical aspects of managing patients with advanced endometrial and cervical cancers and gain insight into experts’ in-clinic strategies for selecting the right treatment for the right patient. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of novel therapeutics, including in conjunction with modern molecular diagnostic testing, in gynecologic cancers, Describe updated evidence on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancers, Integrate approved and emerging options in the management of endometrial and cervical cancer, including in the context of clinical trials, based on disease characteristics and latest recommendations, Discuss the spectrum of unique safety considerations with novel targeted, antibody-based, and immunotherapy regimens in patients with gynecologic cancers.